The high content screening market (HCS) comprises products & services that enable automated, high-throughput analysis of cellular events of biological samples using advanced imaging and analysis tools and technologies.
The report “High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User – Global Forecast to 2030”, global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%.
Download PDF Brochure
The market is driving faster due to various factors such as the launch of technologically advanced instruments and increasing investment in research and development. A significant trend driving market growth is the expanding applications of HCS in personalized medicine, oncology research, and cell-based assays, which are contributing to market growth.
The rising complexity of drug discovery, particularly in oncology, neurodegenerative disorders, and infectious diseases, has increased the reliance on HCS for comprehensive cellular and molecular analysis supporting the market growth. Furthermore, government funding for cell-based research and the rising prevalence of chronic diseases are increasing the adoption of high content screening technologies across various research fields.
The cell detection and analysis system segment is anticipated to grow at a significant CAGR during the forecast period
The market is segmented by instrument into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The high content imaging platforms segment dominated the market in 2024.
High content imaging platforms hold a significant share in the market owing to their critical role in cellular analysis, drug discovery, and phenotypic screening. These platforms enable high-throughput imaging of live and fixed cells, providing detailed cellular morphology and functional insights necessary for drug screening, toxicity assessment, and disease modelling.
Primary and Secondary screening segment dominated the drug discovery & development applications segment in 2024.
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications.
The rising focus on precision medicine, personalized therapies, and high-throughput screening applications has reinforced the demand for high content imaging systems in research and clinical settings.
Pharmaceutical & Biotechnology Companies segment led the end users’ segment in 2024.
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during the forecast period of 2025-2030.
Dominance of the segment is attributable to increasing complexity of drug candidates, particularly in oncology, immunology, and neurological disorders, which has further boosted the demand for HCS in cellular imaging and phenotypic screening. Moreover, the growing trend of precision medicine and biologics development also contributes to the increased utilization of HCS technologies, which is supporting the segment growth in high content screening market.
Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period of 2025-2030
The high content screening market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a strong presence of leading academic institutions and market players, substantial investments in biotechnology and pharmaceutical research, and advanced healthcare infrastructure.
Asia-Pacific (APAC) is witnessing rapid growth, due to the rising prevalence of chronic diseases, increasing healthcare investments, and expanding research capabilities. Countries like China, India, and Japan are experiencing substantial advancements in biotechnology and drug discovery, supporting to the growing demand for high content screening technologies.
The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc.
(US), among others.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
